Executive Summary

A 2026 peer-reviewed study led by public health researcher Danielle F. Haley analyzed 28,069 participants… across 15 urban metropolitan statistical areas in 13 U.S. states examined whether daily opioid use among people who inject drugs (PWID) changed after states expanded cannabis laws from medical-only to medical plus recreational access.

Researchers found a statistically significant association between recreational cannabis legalization and lower probabilities of daily opioid misuse within this population. The study does not establish causation and does not measure overdose outcomes.

In Plain English

A 2026 peer-reviewed study examined whether daily opioid use among people who inject drugs changed in states that expanded cannabis laws from medical-only to medical plus recreational access.

Across 28,069 participants in 15 urban metropolitan statistical areas, researchers found that daily opioid use was 9 to 11 percentage points lower in states with both medical and recreational cannabis laws compared with states that had medical-only laws.

The finding reflects an association within the study model. It does not prove that cannabis legalization caused the reduction.

What the Study Measured

The study used data from the CDC’s National HIV Behavioral Surveillance (NHBS) system. Survey waves occurred in 2012, 2015, 2018, and 2022.

Participants were asked about opioid use during the previous 12 months. Daily use was defined within that recall period.

Researchers examined two primary outcomes:

• Any opioid misuse (heroin or non-medical opioid painkillers)
• Injection opioid misuse

The study population was limited to people who inject drugs in urban metropolitan areas.

How Cannabis Laws Were Classified

States were categorized according to cannabis policy status at the time of data collection:

• No legalization
• Medical cannabis legalization (MCL) only
• Medical + recreational cannabis legalization (MCL + RCL)

Legalization status was coded based on when retail sales became operational, not simply when legislation was passed.

What the Study Found

Using a staggered adoption difference-in-differences model, the researchers reported:

• A 9 percentage point lower probability of daily “any opioid misuse” in MCL + RCL states compared with MCL-only states
• An 11 percentage point lower probability of daily injection opioid misuse

The reported confidence intervals did not cross zero, indicating statistical significance within the model framework.

What Is Difference-in-Differences?

Difference-in-differences is a statistical method commonly used in policy research. It compares how outcomes change over time between groups exposed to a policy and groups that are not.

In simplified terms, the model asks:

Did daily opioid use change differently in states that expanded cannabis laws compared with states that did not?

The method relies on an assumption that groups would have followed similar trends in the absence of the policy change.

With only four survey waves available, formal pre-trend testing was limited, reducing the ability to directly assess that assumption.

Limitations

Several important limitations apply:

Observational Design

The study was not a randomized experiment. It cannot prove that cannabis legalization caused the observed changes.

Serial Cross-Sectional Data

The NHBS surveys did not follow the same individuals over time. Each wave sampled new participants.

Population Scope

Findings apply only to people who inject drugs in urban metropolitan areas. They do not represent the general population.

No Overdose or Prescription Data

The study did not measure overdose deaths, prescription rates, or hospitalizations.

Structural Market Factors

The model did not include a direct measure of fentanyl supply shifts or other changes in illicit drug markets over the study period.

The Careful Takeaway

A 2026 multistate study found an association between recreational cannabis legalization and lower daily opioid use among people who inject drugs in urban settings.

The finding is statistically significant within the model used.

However, the study does not establish causation, does not measure overdose outcomes, and does not directly account for all structural changes in opioid markets over the past decade.

Conclusion

A 2026 peer-reviewed study examining 28,069 participants across 15 urban metropolitan areas found a statistically significant association between recreational cannabis legalization and lower probabilities of daily opioid misuse among people who inject drugs.

The findings apply to a specific urban population and reflect modeled associations within an observational design. The study does not establish causation and does not measure overdose outcomes.

As with most policy research using real-world data, interpretation depends on understanding both the statistical framework and its limitations.

Editorial Note — March 5, 2026

This article was updated to include the original peer-reviewed research source used in the reporting. The study led by public health researcher Danielle F. Haley examining cannabis legalization and opioid use patterns among people who inject drugs was added as a primary citation. HempJuana periodically reviews research-based articles to ensure that source material remains accessible and accurately represented.

The post 2026 Study Links Recreational Cannabis to Lower Daily Opioid Use appeared first on HempJuana.